Lixte Biotechnology Holdings Inc. has announced a strategic expansion from a single-mechanism biotech company to a diversified oncology platform. The company plans to build on its proprietary PP2A inhibitor, LB-100, by incorporating additional complementary treatment modalities. This includes the acquisition of Liora Technologies and the integration of a radiotherapy system into its portfolio. Lixte aims to broaden its asset base, diversify value delivery, and develop a more comprehensive oncology strategy that addresses multiple aspects of cancer treatment. The company intends to operate at the intersection of systemic therapy and radiotherapy, focusing on enhancing clinical outcomes through combined and complementary approaches. Multiple clinical trials targeting solid tumors with unmet medical needs are ongoing, and Lixte holds a comprehensive patent portfolio supporting its development efforts.